Quantification and follow-up during 3 years of circulating tumoral DNA in patients with choroidal melanoma
This study is a prospective, open-labelled, monocentric trial. The aim is to observe, in patient with choroidal melanoma (any stage of the disease), the prevalence of the circulating tumor DNA at the diagnostic and its evolution during 3 years. The patient will have a blood sample at the following times : * T0: before treatment of the primary tumor. * T1: 1 months after the end of the local treatment. * T2: at 7 months. * Tn: every 6 months up to 3 years.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
800
3 vials of 7,5 ml of peripherical blood will be collected at each blood sample.
Institut Curie
Paris, France
Assesment of the change of the circulating tumor DNA from baseline at 3 years
Time frame: T0: before treatment; T1: 1 month after local treatment; T2: at 7 months; Tn : every 6 months up to 3 years.
Compare the treatment effects of the primary tumor (protontherapy, iodine plaque, enucleation) on the rate of circulating tumoral DNA.
Time frame: 3 years
Comparison of the circulating tumor DNA rate to hepatic imaging if available.
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.